The efficacy and safety of autologous gamma/delta T cell transfer therapy after resection of stage2A (T2N0,T3N0) esophageal cancer

The efficacy and safety of autologous gamma/delta T cell transfer therapy after resection of stage2A (T2N0,T3N0) esophageal cancer - Autologous gamma/delta T cell therapy after resection of esophageal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002839

Enrollment

Registered

2009-12-03

Start date

2009-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Gamma/delta T cells are injected on day0, day7, day14, day21, day35, day49, day63, day77.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Esophageal cancer patients who received curative resection and are histopathologically diagnosed as T2N0 or T3N0: -Performance status is 0-2; -20 years or more; -No serious abnormality in heart, lung, bone marrow, liver, and renal functions.

Exclusion criteria

Exclusion criteria: Patients who have: -Pulmonary fibrosis or interstitial pneumonia, including their history or predisposition; -Serious drug allergy; -Difficult infections to control; -Serious cardiac diseases; -Active enteritis; -Active autoimmune diseases; -Other cancers; -Continuous systemic administration of steroids and/or immunosuppressants within 4 weeks.

Design outcomes

Primary

Measure	Time frame
Recurrence rate Recurrence-free survival	—

Secondary

Measure	Time frame
Overall survival Survival rate Response of tumor-related markers Immunological responses Safety	—

Countries

Japan

Contacts

Public ContactKazuhiro Kakimi

The University of Tokyo, Graduate School of Medicine Department of Immunotherapeutics

immunotherapy-admin@umin.ac.jp03-5805-3161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026